{"id":"W3194931521","doi":"10.1016/s1474-4422(21)00237-4","title":"Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Neurology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":192,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of British Columbia; McGill University; NeuroRx Research (Canada)","funders":"National Institutes of Health; Sanofi","keywords":"Medicine; Multiple sclerosis; Placebo; Cohort; Internal medicine; Interferon beta-1a; Pathology; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002182968,0.002552028,0.004933151,0.0005087461,0.0006214192,0.001644145,0.00104247,0.003768866,0.007251218],"category_scores_gemma":[0.002772839,0.0009340851,0.002907824,0.000568476,0.001597172,0.001702292,0.0003971423,0.004203349,0.001574303],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009363372,"about_ca_system_score_gemma":0.0009121417,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001069699,"about_ca_topic_score_gemma":0.001529056,"domain_scores_codex":[0.9990811,0.0004109572,0.00007579731,0.0002025818,0.00007942755,0.0001501269],"domain_scores_gemma":[0.9987803,0.0004148432,0.0002945379,0.00009015958,0.00009509545,0.000325021],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9862255,0.001237126,0.000283167,0.0009369792,0.001071436,0.00003396512,0.0000310336,0.0001388529,0.001687209,0.00006231962,0.0006498466,0.007642655],"study_design_scores_gemma":[0.9794031,0.01814336,0.001028939,0.00004545803,0.000560409,0.00002796403,0.00001236879,0.0001343116,0.0001650547,0.00009769719,0.000368872,0.00001244633],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9575306,0.02934473,0.0009281478,0.001737705,0.001358832,0.002483846,0.002477271,0.0002010124,0.003937872],"genre_scores_gemma":[0.9769089,0.009043441,0.001057796,0.002309081,0.001035886,0.002917439,0.002542599,0.00004742407,0.004137433],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007251218,"threshold_uncertainty_score":0.02425778,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1181872174142568,"score_gpt":0.3653213659137695,"score_spread":0.2471341484995127,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}